{"id":"W4385514316","doi":"10.3324/haematol.2022.281780","title":"Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria","year":2023,"lang":"en","type":"letter","venue":"Haematologica","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"Swedish Orphan Biovitrum; BioCryst; Apellis Pharmaceuticals; Regeneron Pharmaceuticals; UCB Pharma; Alexion Pharmaceuticals; Amgen","keywords":"Paroxysmal nocturnal hemoglobinuria; Hemoglobinuria; Medicine; Internal medicine; Anemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000767337,0.0003441751,0.0008329743,0.0001886503,0.0004691252,0.0007189832,0.0007238021,0.005006547,0.0063299],"category_scores_gemma":[0.00143291,0.0001600907,0.0006115197,0.0002622061,0.0003600584,0.0005495724,0.000177954,0.003273783,0.001592316],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008772663,"about_ca_system_score_gemma":0.000647336,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009038583,"about_ca_topic_score_gemma":0.003053465,"domain_scores_codex":[0.9996674,0.0001459785,0.00002269387,0.00002781798,0.00006424674,0.00007194292],"domain_scores_gemma":[0.9992539,0.0003432053,0.00007993152,0.00002695816,0.0000530607,0.0002429756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.07271931,0.002225212,0.005257251,0.001485472,0.0008162635,0.009110217,0.0001491507,0.0008436175,0.01063978,0.0035957,0.5885355,0.3046226],"study_design_scores_gemma":[0.1878843,0.02917653,0.01807167,0.001097609,0.0008140018,0.01173337,0.0003439239,0.002993977,0.006741033,0.01045315,0.7306108,0.0000796125],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.1528434,0.1491581,0.001947814,0.5686402,0.03525648,0.001535193,0.005029912,0.0003714171,0.08521757],"genre_scores_gemma":[0.6128189,0.04161352,0.002410315,0.2620241,0.01608179,0.001295495,0.003717703,0.00007648431,0.05996161],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.0063299,"threshold_uncertainty_score":0.02117562,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.112899291390924,"score_gpt":0.3572159072057279,"score_spread":0.2443166158148039,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}